Compare GSK plc (GSK) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Regeneron Pharmaceuticals Inc — how do they compare? GSK plc trades at $50.56 (market cap $102.60B), while Regeneron Pharmaceuticals Inc trades at $794.9 (market cap $82.06B). The key difference: GSK plc is the larger of the two by market cap, and GSK plc pays the higher dividend (3.57%). Which is the better fit depends on your goals.
| GSK | REGN | |
|---|---|---|
Market Cap | $102.60B | $82.06B |
Sector | Health | Health |
52-Week High | $61.18 | $812.27 |
52-Week Low | $38.22 | $555.51 |
Enterprise Value | $123.04B | $76.77B |
Dividend Yield | 3.57% | 0.47% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
